Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2013.
Genetic Analysis closes $2mm financing
Norwegian molecular diagnostics firm Genetic Analysis AS raised $2mm in an early-stage financing to Norsk Innovasjonskapital AS. (Oct.)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
But the French major is still keen on early-stage M&A.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.
